JAMA Neurology : Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease
Interview with Charbel Moussa, MD, PhD, author of Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - December 16, 2019 Category: General Medicine Source Type: podcasts
Update on ENESTop: TFR in CML after discontinuing nilotinib
The ENESTop trial (NCT01698905) investigated treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) after discontinuing nilotinib, following the acheivement of a deep molecular...
Author: VJHemOnc
Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Pros And Cons Of CML First-Line Therapy
Giuseppe Saglio, MD of the University of Turin, Turin, Italy discusses the pros and cons of chronic myeloid leukemia (CML) first-line therapy, including imatinib, nilotinib and dasatinib. Prof Saglio ...
Author: VJHemOnc
Added: 07/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - July 22, 2016 Category: Cancer & Oncology Source Type: podcasts
ASH 2014: Phase II EWALL-PH-02 trial shows that nilotinib in addition to standard chemotherapy achieves remission in elderly patients with Philadelphia-positive acute lymphocytic leukaemia
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Oliver Ottmann (Goethe-University Hospital, Frankfurt, Germany) discusses a Trial of the European Working ...
Author: EMJ
Added: 12/09/2014 (Source: Oncology Tube)
Source: Oncology Tube - December 9, 2014 Category: Cancer & Oncology Source Type: podcasts
News from ASCO: Could Some Patients Stop Taking Medication for CML? (B)
Jeffrey Lipton discusses news from ASCO 2012 about how Tasigna could bring faster and deeper responses, taking some newly diagnosed patients all the way to Complete Molecular Response (CMR) well withi...
Author: patientpower
Added: 02/20/2013 (Source: Oncology Tube)
Source: Oncology Tube - February 21, 2013 Category: Cancer & Oncology Source Type: podcasts
